| Objective:To investigate the clinical characteristics and MYC, BCL2geneabnormalities in patients diagnosed with DLBCL concurrent with Hepatitis Bvirus infection.Methods:42patients with DLBCL were enrolled in the study.26patients were male,16patients were female; the median age of42patients was52years (13～77years); Of42patients with DLBCL,17patients with hepatitis B virus infection(group A) and25patients without hepatitis B virus infection (group B). Weretrospectively analyzed clinical characteristics of42patients with DLBCL.MYC, BCL2gene abnormalities of patients with DLBCL were investigated byfluorescence in situ hybridization on formalin-fixed and paraffin-embeddedtissue. To investigate whether advanced clinical prognosis of DLBCLs withHBV infection were associated with MYC and BCL2gene abnormalities. Thedata of the study were analyzed by SPSS16.0, and P＜0.05was regarded with asignificantly difference.Results:1. Clinical characteristics sex: male to female, in group A and group B,was1.8to1.0and1.5to1.0, respectively, there was no significantly differencebetween two groups (P=0.758). age: the ratios of patients with age≤60years, ingroup A and group B, was82.4%and84.0%, respectively, there was also no significantly difference between two groups (P=1.000). clinical stages: patientswith advanced clinical stages were popular between two groups, the ratios, ingroup A and group B, was64.7%and52.0%respectively, there was also nosignificantly difference (P=0.414).2. Factors associated with prognosis IPI score: the ratios of patients withIPI≥3, in group A and group B, was41.2%and8.0%, respectively, there wassignificantly difference (P=0.029)。Subgroup: patients with non-GCB wereprevailing between two groups, the radios, in group A and group B, was70.6%and52.0%respectively, there was no significantly difference (P=0.228).3. MYC, BCL2gene abnormalities: In group A, there were23.5%(4/17)patients with MYC gene abnormalities and29.4%(5/17) patients with BCL2gene abnormalities, of those patients with MYC gene abnormalities,17.6%(3/17) cases with MYC gene break apart rearrangement and5.9%(1/17) casewith MYC gene deletion; of those patients with BCL2gene abnormalities,23.5%(4/17) patients with BCL2gene abnormalities and5.9%(1/17) case withBCL2gene deletion. In group B, there were16.0%(4/25) patients with MYCgene abnormalities and4.0%(1/25) patients with BCL2gene abnormalities, ofthose patients with MYC gene abnormalities,12.0%(3/25) cases with MYCgene break apart rearrangement and4.0%(1/25) cases with MYC gene deletion;one patient with BCL2gene abnormalities was referred to the patient with BCL2gene break apart rearrangement. In group A,4patients with MYC geneabnormalities were non-GCB; while4patients with MYC gene abnormalitieswere GCB in group B.4. As to March,2015, there were38DLBCLs followed up more than1year.Of those,13cases were in group A and25cases were in group B. The mediansurvival of patients, in group A and group B, was39.5months and53.7months,respectively, there was no difference between two groups for survival time(P=0.931). Conclusions:1. DLBCLs with HBV infection presented advanced clinical stage, high IPIscore and prevalent non-GCB subset.2. The ratio of MYC and BCL2gene abnormalities in group A wassignificantly higher than that in group B.3. Different from DLBCLs with MYC gene abnormalities in group B,DLBCLs with MYC gene abnormalities in group A may be mainly derived fromnon-GCB, which indicated MYC gene abnormalities making B cell activatingmay be associated with the pathogenesis of DLBCLs with HBV infection.4. Dismal survival and adverse prognosis of patients may be associatedwith advanced clinical stage, high IPI score, prevalent non-GCB subset and highincidence of MYC and BCL2gene abnormalities in group A. |
PDF Full Text Request